News

Israeli Pharmaceutical Companies See Decline in Shares

1 Mins read

Shares of Israeli pharmaceutical companies have experienced a drop in premarket trading on Monday in the aftermath of the recent attack by Hamas on Israel.

Teva Pharmaceutical Industries Ltd.

Israeli pharmaceutical giant, Teva Pharmaceutical Industries Ltd. (TEVA), has seen a 4% decrease in its shares.

Taro Pharmaceutical Industries Ltd.

Shares of Taro Pharmaceutical Industries Ltd. (TARO) have also been impacted, with a decrease of 2.6%.

Kamada Ltd.

Biopharmaceutical company, Kamada Ltd. (KMDA), has observed a significant decline of 6.1% in its stock value.

Protalix BioTheraputics Inc.

The stock of Protalix BioTheraputics Inc. (PLX) has experienced a decrease of 5.5%.

Protalix released a statement expressing their condolences and solidarity with the victims of the ongoing attacks in Israel. However, they reassured their employees, partners, and stockholders that their operations remain unaffected by the situation and that there will be no disruption to the supply of their products.

Compugen Ltd.

Drug discovery and development company, Compugen Ltd. (CGEN), has witnessed a 6.6% decrease in shares on Monday.

Gamida Cell Ltd.

Gamida Cell Ltd. (GMDA) has experienced a decline of 7.4% in premarket trades on Monday.

These recent developments highlight the impact of the attack on Israeli society, including its pharmaceutical industry.

Related posts
News

ROYAL STARS | GEORGIA NICOLS

3 Mins read
Happy Birthday for Thursday, Aug. 7, 2025: You want to help others, individually or on a larger scale. You’re determined, perceptive and…
News

Traders Burned by August Meltdown Keep Betting on Japan Stocks

1 Mins read
A year after an epic rebound in the yen upended currency trading and sent shares tumbling from Tokyo to New York, Japan’s…
News

SEC Rule Change Could Reduce Bitcoin Volatility, Boost Institutional Demand - TokenPost

1 Mins read
Bitcoin’s trademark volatility may be entering a new phase following a recent U.S. Securities and Exchange Commission (SEC) decision. The regulator has…

Leave a Reply

Your email address will not be published. Required fields are marked *